Drug Trial Radar · NCT03334747
Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.
Last checked: Nov 19, 2026Latest source record: Oct 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
188
Actual
Start
Nov 16, 2017
Primary completion
Nov 23, 2019
Study completion Nov 23, 2019
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- Collaborators
- Wellcome Trust
- First posted
- Nov 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
KAE609 will be evaluated primarily for hepatic safety of single and multiple doses in sequential cohorts with increasing doses.This study aims to determine the maximum safe dose of the investigational drug KAE609 in malaria patients.
Conditions
- Malaria
Interventions
KAE609Drug
Exploration of different doses of KAE609 to establish safety profile.
CoartemDrug
Control Arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With at Least 2 CTCAE Grades Increase From Baseline in Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST)Time frame: Day 29
Locations
9 sites in 5 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Lambaréné, Gabon
Novartis Investigative Site
Kintampo, Ghana
Novartis Investigative Site
Navrango, Ghana
Novartis Investigative Site
Bamako, Mali
Novartis Investigative Site
Sotouba, Mali
Novartis Investigative Site
Kigali, Rwanda
Novartis Investigative Site
Bushenyi, Uganda
Novartis Investigative Site
Kampala, Uganda
Novartis Investigative Site
Tororo, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.